Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Ain-Shams Journal of Forensic Medicine and Clinical Toxicology. 2005; 4: 60-68
em Inglês | IMEMR | ID: emr-69283

RESUMO

Doxorubicin or adriamycin [DXR] is a potent chemotherapeutic agent used in treatment of certain neoplastic diseases. Toxicity of Doxorubicin has been reported to be reduced by co-treatment with antioxidant and potent heavy metal chelators as deferroxamine. To evaluate such effect on Doxorubicin induced teratogenesis, twenty four pregnant female albino rats were equally divided into 3 groups. The first group was served as a control group. The second group was injected intraperitoneally [IP] with DXR [3.6 mg /kg B.W.] while the third group was injected by Deferroxamine [250 mg /Kg] 30 minutes before DXR injection [3.6 mg /kg B.w]. On the 20 th - gestation day, dams were sacrificed and examined. There was a high embryo toxic effect [80%] in dams of the second group. While in Deferroxamine treated, rats the resorption decreased to 45.8% and fetuses had numerous malformations as malformed vertebrae, wavy ribs, absence of femur, radius, ulna, tibia, fibula and metacarpal bones. Theses results recommended councelling pregnant female about doxurubicin teratogenic effect and protective role of Deferroxamine in such condition


Assuntos
Feminino , Animais de Laboratório , Prenhez/efeitos dos fármacos , Ratos , Desenvolvimento Fetal , Substâncias Protetoras , Desferroxamina/farmacologia , Reprodução , Teratogênicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA